Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status

Abstract Background Introducing neoadjuvant chemotherapy (NCT) in a breast cancer patient may be associated with changes in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) status. Method In our prospective cohort study, we evaluated the impact of change in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) on the prognosis of breast cancer patients treated with neoadjuvant chemotherapy (NCT). We investigated 110 patients with locally advanced breast cancer for ER, PR and HER2 status of their lesions before and after NCT. Result For hormone receptor status (HR) (which include ER, PR) of the residual tumor of the patients after receiving NCT, 12 (10.9%) of them changed from HR (+) to HR (−) and 15 (13.6%) changed from HR (−) to HR (+). For HER2 status after NCT, 8 (7.3%) patients changed from HER2 (+) to HER2 (−) and 9 (8.2%) patients changed from HER2 (−) to HER2 (+). Triple negative (TN) tumor phenotype changes occurred in 17 (15.5%) patients. Patients for whom the HR status changed from positive to negative had poor prognosis for both disease-free survival (DFS) and overall survival (OS) in univariate survival analysis. Conclusion Changes in ER, PR, HER2 status and tumor phenotype in breast cancer patients after NCT had a negative prognostic impact and were associated with a poor prognosis.

Download Full-text

Đánh giá kết quả điều trị tân bổ trợ ung thư vú tại Bệnh viện Ung bướu Đà Nẵng

Journal of Clinical Medicine- Hue Central Hospital ◽

10.38103/jcmhch.2020.65.14 ◽

2020 ◽

Author(s):

Tinh Bui Thanh

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Triple Negative ◽

Ductal Carcinoma ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Breast Conserving Surgery ◽

Lymph Node Biopsy ◽

Her2 Status ◽

Breast Cancer Patients

Background: Neoadjuvant chemotherapy for breast cancer was used to downstaging tumours to facilitate breast-conserving surgery. Methods: A descriptive retrospective study of 93 breast cancer patients at Da Nang Oncology Hospital from January 2017 to December 2019. Patients diagnosed with locally advanced breast cancer cT2-4N0- 3M0. Exclude cases of Ductal carcinoma in situ from breast or previously treated. Results: an average age of 48, an average tumor size of 6.0 cm, the majority were Invasive ductal carcinoma (97.8%) and grade 2 ( 85.6%). Hormon receptor positive in 57%, HER-2 positive in 38.7% and 18.3% triple negative Breast cancer. The combination chemotherapy regimen Anthacycline and Taxane accounted for 94.7%, Trastuzumab-based regimen accounted for 25%. There was 8.3% progression of disease during neoadjuvant chemotherapy. About Surgery: Breast- conserving surgery in 20.5%, Breast reconstruction in 6.8%, Mastectomy in 71.6%, Sentinel lymph node biopsy in 4.3%. Her2 status was significantly different between the groups with and without pCR.. Endocrine receptors are negative, Ki67 is high, and Triple negative has a higher rate of pCR but not statistically significant. Conclusion: Neoadjuvant chemotherapy helps to downstaging tumours to facilitate breast-conserving surgery. Her2 status is correlated with the rate of complete pathological response (pCR).

Download Full-text

Abstract P5-06-12: Validation of residual proliferative cancer burden (RPCB) as a predictor of long-term outcome following neoadjuvant chemotherapy in hormone-receptor positive/HER2 negative breast cancer patients

10.1158/1538-7445.sabcs19-p5-06-12 ◽

2020 ◽

Author(s):

Federica Miglietta ◽

Vassilena Tsvetkova ◽

Maria Vittoria Dieci ◽

Gaia Griguolo ◽

Grazia Vernaci ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Hormone Receptor ◽

Breast Cancer Patients ◽

Term Outcome ◽

Long Term Outcome ◽

Cancer Burden ◽

Hormone Receptor Positive

Download Full-text

Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06100-2 ◽

2021 ◽

Vol 187 (1) ◽

pp. 135-144

Author(s):

Andrew P. Jallouk ◽

Sriram Paravastu ◽

Katherine Weilbaecher ◽

Rebecca L. Aft

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Advanced Breast ◽

Term Outcome ◽

Acid Therapy ◽

Long Term Outcome

Download Full-text

The discordance of the ER, PR, and HER2 status after neoadjuvant chemotherapy in breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e12037 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e12037-e12037

Author(s):

Basak Oven Ustaalioglu ◽

Ahmet Bilici ◽

Fugen Vardar Aker ◽

Burcak Erkol ◽

Mehmet Aliustaoglu ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Core Needle Biopsy ◽

Needle Biopsy ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Her2 Status ◽

Breast Cancer Patients ◽

Core Needle

e12037 Background: Neoadjuvant chemotherapy(NAC) is the accepted approach for women with locally advanced breast cancer with technically inoperable disease. Systemic treatment is mainly based on the presence of the Estrogen (ER) receptor, Progesterone (PR) receptor and HER2 status on the core needle biopsy prior to treatment. Previously, discordance of the hormone receptor (HR) status was reported as 8-33% in the breast cancer patients after NAC. In here, we evaluated the HR and HER2 discordance after NAC in locally advanced breast cancer patients. Methods: We reviewed the data of 849 breast cancer patients retrospectively. The pathological specimens of core needle biopsy and operation specimens were re-evaluated for HR and HER2 status in 38 patients who had been treated with NAC. The changing of HR and HER2 status after chemotherapy was defined as discordance. The relationship between clinicopathological parameters and discordance and significance of them for disease-free survival (DFS) was analyzed by chi-square and univariaty test. Results: Over 80% of patients were clinically stage III breast cancer. Out of 24 patients were premenapouse and median age was 44.5(30-94). The patients were received median 4(1-6) cycles of NAC as 2 of them were only hormonotherapy, 8 were only antracycline and others were both antracycline and taxanes. Nearly 80% of patients were performed modified radical mastectomy(MRM).Postoperatively median tumor size was 1.6cm(0-10) and median dissected lymph nodes was 14(0-28). After operation, 4(10.5%), 8(21.1%) and 8(21.1%) discordance were detected for ER, PR and HER2 respectively. While HER2 discordance were related with recurrence(p=0.01) and PR discordance(p=0.04), ER discordance was related with only patological stage(p=0.03). At the median follow-up of 15.7 months, 5 year DFS rate and time were 30% and 30.4 months(18.7-42.2), respectively. Operation type, stage, lymphovascular invasion, perineural invasion were found to be significant for DFS, HR and HER2 discordance was not related with DFS. Conclusions: Until more definitive results will be obtained from future studies, receptor status of the residual tumor after NAC should be retested.

Download Full-text